Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetic and mass-balance study of BAY 1817080 in healthy men
NL-OMON49615Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of eliapixant in chronic cough and endometriosis (2 arms), sponsored by Bayer. Primary endpoints: Pharmacokinetics of BAY 1817080, Mass balance and route of excretion and 2 more. Started Aug 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic coughendometriosis
Beyond the preview
Go deeper on NL-OMON49615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49615.